Vanguard Group Inc. Has $537.54 Million Holdings in Maximus, Inc. $MMS

Vanguard Group Inc. cut its holdings in shares of Maximus, Inc. (NYSE:MMS) by 2.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,227,259 shares of the health services provider’s stock after selling 174,453 shares during the quarter. Vanguard Group Inc. owned 0.11% of Maximus worth $537,537,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Boston Partners lifted its holdings in shares of Maximus by 47.0% during the 3rd quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock valued at $88,236,000 after buying an additional 308,892 shares during the last quarter. Stephens Investment Management Group LLC lifted its holdings in shares of Maximus by 49.0% during the 3rd quarter. Stephens Investment Management Group LLC now owns 720,943 shares of the health services provider’s stock valued at $65,873,000 after buying an additional 237,097 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Maximus by 115.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 379,342 shares of the health services provider’s stock valued at $26,630,000 after buying an additional 203,521 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Maximus during the 4th quarter valued at about $15,673,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Maximus during the 3rd quarter valued at about $15,397,000. 97.21% of the stock is currently owned by institutional investors and hedge funds.

Maximus Stock Down 1.6%

Shares of Maximus stock opened at $64.51 on Tuesday. The stock has a 50-day simple moving average of $69.28 and a 200-day simple moving average of $80.41. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.34 and a quick ratio of 2.34. Maximus, Inc. has a 52-week low of $60.75 and a 52-week high of $100.00. The firm has a market cap of $3.52 billion, a price-to-earnings ratio of 9.82 and a beta of 0.60.

Maximus (NYSE:MMS) last issued its quarterly earnings data on Thursday, February 5th. The health services provider reported $1.85 earnings per share for the quarter, beating analysts’ consensus estimates of $1.84 by $0.01. Maximus had a return on equity of 25.30% and a net margin of 6.92%.The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.37 billion. During the same period last year, the business earned $1.61 EPS. The firm’s revenue was down 4.1% compared to the same quarter last year. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. On average, equities research analysts expect that Maximus, Inc. will post 8.46 earnings per share for the current fiscal year.

Maximus Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, May 15th will be paid a $0.33 dividend. This represents a $1.32 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Friday, May 15th. Maximus’s dividend payout ratio (DPR) is presently 20.09%.

Insider Activity at Maximus

In related news, Director Jan Madsen sold 742 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $72.25, for a total value of $53,609.50. Following the transaction, the director directly owned 20,795 shares of the company’s stock, valued at approximately $1,502,438.75. This trade represents a 3.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David Mutryn acquired 1,000 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was bought at an average cost of $75.62 per share, for a total transaction of $75,620.00. Following the completion of the purchase, the chief financial officer directly owned 40,037 shares in the company, valued at $3,027,597.94. This represents a 2.56% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wall Street Zen lowered Maximus from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Weiss Ratings lowered Maximus from a “buy (b)” rating to a “hold (c+)” rating in a report on Tuesday, February 24th. Finally, Zacks Research lowered Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold”.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.